Effectivness of Bruton tyrosine kinase in treatment of chronic lymphocytic leukemia

Journal of Cellular Cancer  Volume 5, Issue 2, pages 20-31
Published: December 13, 2013

Kanti W. Christos, Nasser Ghaly Yousif, Carol Tolksdorf, Gregory A. Jones, Steven Delforge  


Chronic lymphocytic leukemia (CLL) is a clonal malignancy of mature B cells that displays a great clinical heterogeneity, and gene-expression profiling and phenotypic studies suggest that CLL is probably derived from CD5+ B cells similar to those found in the blood of healthy adults. Agents that can interfere with B-cell receptor (BCR) signaling or chemokine– receptor signaling, or that target surface antigens selectively expressed on CLL cells, promise to have significant therapeutic benefit in patients with this disease. Downstream of the BCR is Bruton tyrosine kinase (BTK), a signal-transduction kinase that plays a critical role in BCR signaling and B-cell development and function. Loss of BTK in the human disease Bruton X-linked agammaglobulinemia results in the absence of B cells and profound hypogammaglobulinemia. Selective BTK inhibition is an attractive approach for CLL driven by BCR activation. This review has identified the role of BTK in treatment of CLL.

KeywordsChronic lymphocytic leukemia (CLL); B-cell receptor (BCR); Bruton tyrosine kinase (BTK)

Purchase access to this articleReferencesExport Citation
Purchase this article at rate $55.00 and received Full-Text/PDF You will have online immediate access to article following the completion of this purchase and you may download and print a copy of each article for your personal use. Purchase Article


  1. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N. Engl. J. Med 2005;352:804–815. [PubMed]
  2. Soma LA, Craig FE, Swerdlow SH. The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. Hum. Pathol 2006;37:152–159. [PubMed]
  3. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Investig 2005;115:755–764. [PMC free article] [PubMed]
  4. Forconi F, Potter KN, Wheatley I, Darzentas N, Sozzi E, et al. The normal IGHV1-69-derived B cell repertoire contains stereotypic patterns characteristic of unmutated CLL. Blood 2010;115:71–77. [PubMed]
  5. Ha YJ, Mun YC, Seong CM, Lee JR. Characterization of phenotypically distinct B cell subsets and receptor-stimulated mitogen-activated protein kinase activation in human cord blood B cells. J. Leukoc. Biol 2008;84:1557–1564. [PubMed]
  6. Seifert M, Sellmann L, Bloehdorn J, Wein F, Stilgenbauer S, et al. Cellular origin and pathophysiology of chronic lymphocytic leukemia. J. Exp. Med 2012;209:2183–2198. [PubMed]
  7. Ghia P, Prato G, Scielzo C, Stella S, Geuna M, et al. Monoclonal CD5+ and CD5− B lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 2004;103:2337–2342. [PubMed]
  8. Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B cell chronic lymphocytic leukemia. Clin. Cancer Res 2008;14:396–404. [PubMed]
  9. Fukuda T, Chen L, Endo T, Tang L, Lu D, et al. Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a. Proc. Natl. Acad. Sci. USA 2008;105:3047–3052. [PubMed]
  10. Sevilla DW, Colovai AI, Emmons FN, Bhagat G, Alobeid B. Hematogones: a review and update. Leuk. Lymphoma 2010;51:10–19. [PubMed]
  11. Brown JR. The treatment of relapsed refractory chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011;2011:110-118. [PubMed]
  12. Eichhorst BF, Busch R, Hopfinger G, et al. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006;107(3):885–891. [PubMed]
  13. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23(18):4079–4088. [PubMed]
  14. Petro JB, Rahman SM, Ballard DW, Khan WN. Bruton’s tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med 2000;191(10):1745–1754. [PMC free article] [PubMed]
  15. Petro JB, Khan WN. Phospholipase C-gamma 2 couples Bruton’s tyrosine kinase to the NF-kappaB signaling pathway in B lymphocytes. J Biol Chem 2001;276(3):1715–1719. [PubMed]
  16. Herman SE, Gordon AL, Hertlein E, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117(23):6287–6296. [PubMed]
  17. Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111(12):5446–5456. [PMC free article] [PubMed]
  18. Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton’s tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370(24):2286–2294. [PubMed]
  19. Stevenson FK, Krysov S, Davies AJ, Steele AJ, Packham G. B-cell receptor signaling in chronic lymphocytic leukemia. Blood.2011;118(16):4313–4320. [PubMed]
  20. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV. Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br. J. Haematol. 1996;92:97–103. [PubMed]
  21. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of Toll-like receptors in chronic lymphocytic leukaemia cells. Br. J. Haematol 2009;144:507–516. [PubMed]
  22. Tsukada N, Burger JA, Zvaifler NJ, Kipps TJ. Distinctive features of “nurselike” cells that differentiate in the context of chronic lymphocytic leukemia. Blood 2002;99:1030–1037. [PubMed]

Journal of cellular cancer picture







Kanti W. Christos, Nasser Ghaly Yousif, Carol Tolksdorf , Gregory A. Jones, Steven Delforge. Effectivness of Bruton tyrosine kinase in treatment of chronic lymphocytic leukemia. Journal of Cellular Cancer 2013; 5(2): 20-31.